Ceftolozane/tazobactam activity against drug-resistant Enterobacteriaceae and Pseudomonas aeruginosa causing healthcare-associated infections in the Asia-Pacific region (minus China, Australia and New Zealand): report from an Antimicrobial Surveillance Programme (2013–2015)

International Journal of Antimicrobial Agents

Volumn 51, Issue 2, 2018, Pages 181-189

  Pfaller, M A ^a,b   Shortridge, D ^a   Sader, H S ^a   Castanheira, M ^a   Flamm, R K ^a  

^a JMI LABORATORIES   (United States)

^b UNIVERSITY OF IOWA   (United States)

Author keywords

Asia Pacific; Ceftolozane tazobactam; Drug resistance; Enterobacteriaceae; Pseudomonas aeruginosa; Surveillance

Indexed keywords

AMIKACIN; CEFEPIME; CEFTAZIDIME; CEFTOLOZANE PLUS TAZOBACTAM; COLISTIN; MEROPENEM; PIPERACILLIN PLUS TAZOBACTAM; ANTIINFECTIVE AGENT; BETA LACTAMASE INHIBITOR; CEFTOLOZANE, TAZOBACTAM DRUG COMBINATION; CEPHALOSPORIN DERIVATIVE; PENICILLANIC ACID; THIENAMYCIN DERIVATIVE;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; ASIA; AUSTRALIA; BACTERIUM ISOLATE; BROTH DILUTION; CITROBACTER; CONTROLLED STUDY; DRUG SURVEILLANCE PROGRAM; ENTEROBACTER; ENTEROBACTERIACEAE; ESCHERICHIA COLI; HEALTHCARE ASSOCIATED INFECTION; HONG KONG; IN VITRO STUDY; INDIA; KLEBSIELLA; MALAYSIA; MIC50; MIC90; NEW ZEALAND; NONHUMAN; PRIORITY JOURNAL; PROTEUS MIRABILIS; PSEUDOMONAS AERUGINOSA; SERRATIA MARCESCENS; SINGAPORE; SOUTH KOREA; TAIWAN; THAILAND; ANALOGS AND DERIVATIVES; CROSS INFECTION; DRUG EFFECT; ENTEROBACTERIACEAE INFECTION; EPIDEMIOLOGICAL MONITORING; HUMAN; ISOLATION AND PURIFICATION; MICROBIAL SENSITIVITY TEST; MICROBIOLOGY; MULTIDRUG RESISTANCE; PSEUDOMONAS INFECTION; SOUTHEAST ASIA;

AMIKACIN; ANTI-BACTERIAL AGENTS; ASIA, SOUTHEASTERN; BETA-LACTAMASE INHIBITORS; CEPHALOSPORINS; COLISTIN; CROSS INFECTION; DRUG RESISTANCE, MULTIPLE, BACTERIAL; ENTEROBACTERIACEAE; ENTEROBACTERIACEAE INFECTIONS; EPIDEMIOLOGICAL MONITORING; HUMANS; MICROBIAL SENSITIVITY TESTS; PENICILLANIC ACID; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTIONS; THIENAMYCINS;

EID: 85039070364     PISSN: 09248579     EISSN: 18727913     Source Type: Journal    
DOI: 10.1016/j.ijantimicag.2017.09.016     Document Type: Article

References (34)

1. Kollef, M.H., Golan, Y., Micek, S.T., Shorr, A.F., Restrepo, M.I., Appraising contemporary strategies to combat multidrug resistant Gram-negative bacterial infections—proceedings and data from the Gram-Negative Resistance Summit. Clin Infect Dis 53:Suppl. 2 (2011), S33–S55 quiz S56-8.
2. Boucher, H.W., Talbot, G.H., Bradley, J.S., Edwards, J.E., Gilbert, D., Rice, L.B., et al. Bad bugs, no drugs: no ESKAPE! An update from the Infectious Diseases Society of America. Clin Infect Dis 48 (2009), 1–12.
3. Bertrand, X., Dowzicky, M.J., Antimicrobial susceptibility among Gram-negative isolates collected from intensive care units in North America, Europe, the Asia-Pacific Rim, Latin America, the Middle East, and Africa between 2004 and 2009 as part of the Tigecycline Evaluation and Surveillance Trial. Clin Ther 34 (2012), 124–137.
4. Hampton, T., Report reveals scope of US antibiotic resistance threat. JAMA 310 (2013), 1661–1663.
5. European Center for Disease Prevention and Control, Antimicrobial resistance surveillance report Europe 2013. 2014, ECDC, Stockholm, Sweden Available from: http://ecdc.europa.eu/en/publications/Publications/antimicrobial-resistance-surveillance-europe-2013.pdf.
6. Sheng, W.H., Badal, R.E., Hsueh, P.R., SMART Program. Distribution of extended-spectrum β-lactamases, AmpC β-lactamases, and carbapenemases among Enterobacteriaceae isolates causing intra-abdominal infections in the Asia-Pacific region: results of the study for Monitoring Antimicrobial Resistance Trends (SMART). Antimicrob Agents Chemother 57 (2013), 2981–2988.
7. Tan, T.Y., Hsu, L.Y., Koh, T.H., Ng, L.S., Tee, N.W., Krishnan, P., et al. Antibiotic resistance in Gram-negative bacilli: a Singapore perspective. Ann Acad Med Singapore 37 (2008), 819–825.
8. Ashley, E.A., Lubell, Y., White, N.J., Turner, P., Antimicrobial susceptibility of bacterial isolates from community acquired infections in sub-Saharan Africa and Asian low and middle income countries. Trop Med Int Health 16 (2011), 1167–1179.
9. Bell, J.M., Turnidge, J.D., Gales, A.C., Pfaller, M.A., Jones, R.N., Sentry, A.S.G., Prevalence of extended spectrum β-lactamase (ESBL)-producing clinical isolates in the Asia-Pacific region and South Africa: regional results from SENTRY Antimicrobial Surveillance Program (1998–99). Diagn Microbiol Infect Dis 42 (2002), 193–198.
10. Jean, S.S., Hsueh, P.R., High burden of antimicrobial resistance in Asia. Int J Antimicrob Agents 37 (2011), 291–295.
11. Sader, H.S., Flamm, R.K., Jones, R.N., Antimicrobial activity of ceftaroline and comparator agents tested against bacterial isolates causing skin and soft tissue infections and community-acquired respiratory tract infections isolated from the Asia-Pacific region and South Africa (2010). Diagn Microbiol Infect Dis 76 (2013), 61–68.
12. Cosgrove, S.E., The relationship between antimicrobial resistance and patient outcomes: mortality, length of hospital stay, and health care costs. Clin Infect Dis 42:Suppl. 2 (2006), S82–S89.
13. Sievert, D.M., Ricks, P., Edwards, J.R., Schneider, A., Patel, J., Srinivasan, A., et al. Antimicrobial-resistant pathogens associated with healthcare-associated infections: summary of data reported to the National Healthcare Safety Network at the Centers for Disease Control and Prevention, 2009–2010. Infect Control Hosp Epidemiol 34 (2013), 1–14.
14. Zhang, D., Micek, S.T., Kollef, M.H., Time to appropriate antibiotic therapy is an independent determinant of postinfection ICU and hospital lengths of stay in patients with sepsis. Crit Care Med 43 (2015), 2133–2140.
15. Giancola, S.E., Mahoney, M.V., Bias, T.E., Hirsch, E.B., Critical evaluation of ceftolozane–tazobactam for complicated urinary tract and intra-abdominal infections. Ther Clin Risk Manag 12 (2016), 787–797.
16. van Duin, D., Bonomo, R.A., Ceftazidime/avibactam and ceftolozane/tazobactam: second-generation β-lactam/β-lactamase inhibitor combinations. Clin Infect Dis 63 (2016), 234–241.
17. Daxboeck, F., Budic, T., Assadian, O., Reich, M., Koller, W., Economic burden associated with multi-resistant Gram-negative organisms compared with that for methicillin-resistant Staphylococcus aureus in a university teaching hospital. J Hosp Infect 62 (2006), 214–218.
18. Boucher, H.W., Talbot, G.H., Benjamin, D.K. Jr, Bradley, J., Guidos, R.J., Jones, R.N., et al. 10 × ‘20 progress—development of new drugs active against Gram-negative bacilli: an update from the Infectious Diseases Society of America. Clin Infect Dis 56 (2013), 1685–1694.
19. Farrell, D.J., Flamm, R.K., Sader, H.S., Jones, R.N., Antimicrobial activity of ceftolozane–tazobactam tested against Enterobacteriaceae and Pseudomonas aeruginosa with various resistance patterns isolated in U.S. hospitals (2011–2012). Antimicrob Agents Chemother 57 (2013), 6305–6310.
20. Farrell, D.J., Sader, H.S., Flamm, R.K., Jones, R.N., Ceftolozane/tazobactam activity tested against Gram-negative bacterial isolates from hospitalized patients with pneumonia in United States and European medical centres (2012). Int J Antimicrob Agents 43 (2014), 533–539.
21. Sader, H.S., Farrell, D.J., Castanheira, M., Flamm, R.K., Jones, R.N., Antimicrobial activity of ceftolozane/tazobactam tested against Pseudomonas aeruginosa and Enterobacteriaceae with various resistance patterns isolated in European hospitals (2011–2012). J Antimicrob Chemother 69 (2014), 2713–2722.
22. Sader, H.S., Farrell, D.J., Flamm, R.K., Jones, R.N., Ceftolozane/tazobactam activity tested against aerobic Gram-negative organisms isolated from intra-abdominal and urinary tract infections in European and United States hospitals (2012). J Infect 69 (2014), 266–277.
23. Sader, H.S., Rhomberg, P.R., Farrell, D.J., Jones, R.N., Antimicrobial activity of CXA-101, a novel cephalosporin tested in combination with tazobactam against Enterobacteriaceae, Pseudomonas aeruginosa, and Bacteroides fragilis strains having various resistance phenotypes. Antimicrob Agents Chemother 55 (2011), 2390–2394.
24. Clinical and Laboratory Standards Institute, Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically; approved standard. 30th ed, 2015, CLSI, Wayne, PA Document M07-A10.
25. Clinical and Laboratory Standards Institute, Performance standards for antimicrobial susceptibility testing. 27th ed, 2017, CLSI, Wayne, PA Document M100.
26. European Committee on Antimicrobial Susceptibility Testing, Breakpoint tables for interpretation of MICs and zone diameters. Version 7.0; Available from: http://www.eucast.org/clinical_breakpoints/, 2017.
27. Magiorakos, A.P., Srinivasan, A., Carey, R.B., Carmeli, Y., Falagas, M.E., Giske, C.G., et al. Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance. Clin Microbiol Infect 18 (2012), 268–281.
28. Farrell, D.J., Turnidge, J.D., Bell, J., Sader, H.S., Jones, R.N., The in vitro evaluation of tigecycline tested against pathogens isolated in eight countries in the Asia-Western Pacific region (2008). J Infect 60 (2010), 440–451.
29. Hirakata, Y., Matsuda, J., Miyazaki, Y., Kamihira, S., Kawakami, S., Miyazawa, Y., et al. Regional variation in the prevalence of extended-spectrum β-lactamase-producing clinical isolates in the Asia-Pacific region (SENTRY 1998–2002). Diagn Microbiol Infect Dis 52 (2005), 323–329.
30. Turnidge, J., Bell, J., Biedenbach, D.J., Jones, R.N., Pathogen occurrence and antimicrobial resistance trends among urinary tract infection isolates in the Asia-Western Pacific region: report from the SENTRY Antimicrobial Surveillance Program, 1998–1999. Int J Antimicrob Agents 20 (2002), 10–17.
31. Chen, Y.H., Hsueh, P.R., Badal, R.E., Hawser, S.P., Hoban, D.J., Bouchillon, S.K., et al. Antimicrobial susceptibility profiles of aerobic and facultative Gram-negative bacilli isolated from patients with intra-abdominal infections in the Asia-Pacific region according to currently established susceptibility interpretive criteria. J Infect 62 (2011), 280–291.
32. Jones, R.N., The emergent needs for basic research, education, and surveillance of antimicrobial resistance. Problems facing the report from the American Society for Microbiology Task Force on Antibiotic Resistance. Diagn Microbiol Infect Dis 25 (1996), 153–161.
33. Ko, W.C., Hsueh, P.R., Increasing extended-spectrum β-lactamase production and quinolone resistance among Gram-negative bacilli causing intra-abdominal infections in the Asia/Pacific region: data from the SMART study 2002–2006. J Infect 59 (2009), 95–103.
34. Perez, F., Villegas, M.V., The role of surveillance systems in confronting the global crisis of antibiotic-resistant bacteria. Curr Opin Infect Dis 28 (2015), 375–383.